Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference

HOUSTON, May 31, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 at 2:00 p.m. EDT in New York, NY.

A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.



Investors:
Bellicum PharmaceuticalsAlan Musso, CFO
832-384-1116
amusso@bellicum.com

Media:
BMC CommunicationsBrad Miles
646-513-3125
bmiles@bmccommunications.com

Primary Logo

Bellicum Pharmaceuticals